GSK plc (BVMF:G1SK34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 524.48B +20.2% |
| Revenue (ttm) | 228.23B +5.0% |
| Net Income | 33.14B +40.8% |
| EPS | 8.10 +42.6% |
| Shares Out | n/a |
| PE Ratio | 15.83 |
| Forward PE | 9.95 |
| Dividend | 1.74 (3.31%) |
| Ex-Dividend Date | Aug 13, 2026 |
| Volume | 375 |
| Open | 52.28 |
| Previous Close | 52.30 |
| Day's Range | 52.28 - 52.60 |
| 52-Week Range | 42.40 - 63.24 |
| Beta | 0.30 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 28, 2026 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2025, GSK plc's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.
Financial numbers in GBP Financial StatementsNews
GSK’s ViiV Healthcare announces FDA approval of Tivicay PD
ViiV Healthcare, the global specialist HIV company majority owned by GSK (GSK), with Shionogi as a shareholder, announced that the U.S. FDA has approved Tivicay PD, for use in combination…
Noetik Achieves First Milestone in Landmark GSK Collaboration
SAN FRANCISCO--(BUSINESS WIRE)-- #GSK--Noetik achieves first milestone in landmark GSK collaboration.
GSK price target raised to 1,900 GBp from 1,750 GBp at Morgan Stanley
Morgan Stanley raised the firm’s price target on GSK (GSK) to 1,900 GBp from 1,750 GBp and keeps an Underweight rating on the shares.
AnaptysBio price target lowered to $70 from $75 at TD Cowen
TD Cowen lowered the firm’s price target on AnaptysBio (ANAB) to $70 from $75 and keeps a Buy rating on the shares. The firm updated its model after GSK (GSK)…
GSK announces Japan’s MHLW approved Hibsago
GSK (GSK) announced that Japan’s Ministry of Health, Labour and Welfare, MHLW, has approved Hibsago, an antisense oligonucleotide, ASO, as a functional cure for chronic hepatitis B, CHB, virus infecti...
GSK announces FDA accepted for priority review a sBLA for Jemperli
GSK (GSK) announced the US Food and Drug Administration, FDA, has accepted for priority review a supplemental Biologics License Application, sBLA, for Jemperli for patients with previously untreated s...
GSK scores regulatory wins for chronic hepatitis B drug, cancer therapy
GSK said on Monday its experimental chronic hepatitis B drug received its first global approval in Japan, and a key cancer therapy was granted a priority U.S. regulatory review as a possible rectal ...
Trump wants to split the MMR vaccine. Experts say that's unlikely — and comes with consequences
President Donald Trump's latest executive order calls for splitting the measles, mumps and rubella, or MMR, vaccine into three separate shots. But doctors and other experts say that effort has no scie...
GSK India first-quarter profit rises on steady vaccine demand
Vaccine maker GlaxoSmithKline Pharmaceuticals reported a 15.7% rise in first-quarter profit on Monday, aided by stable demand across its vaccine and drug portfolio, including respiratory and special...
GSK closer to relaunching Brexafemme, says Brookline
Brookline notes that the FDA’s daily drug safety related labeling changes includes changes to Brexafemme’s label, which the firm calls “concrete evidence” that GSK (GSK) is closer to relaunching Brexa...
Drugmakers, retailers must face 'maximum strength' claim in decongestant false ad litigation in US
A federal appeals court on Thursday revived portions of nationwide litigation in which consumers accused drugmakers such as Procter & Gamble and retailers such as CVS of selling billions of dollars o...
GSK price target raised to 2,000 GBp from 1,950 GBp at Deutsche Bank
Deutsche Bank raised the firm’s price target on GSK (GSK) to 2,000 GBp from 1,950 GBp and keeps a Hold rating on the shares.
GSK, Relation Therapeutics sign up to $110 million AI drug discovery deal
British biotech firm Relation Therapeutics said on Wednesday it had entered into a research collaboration with GSK worth up to $110 million to generate human cellular datasets and train AI models ...
Cabenuva demonstrates superiority to daily oral therapy in adolescents with HIV
GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK with Shionogi as a shareholder, announced data to be presented this week at the 26th…
GSK Q2 Earnings Call Highlights
GSK NYSE: GSK reported second-quarter sales growth of 5% at constant exchange rates to more than £8.4 billion, supported by Specialty Medicines and Vaccines, while outlining a new cost-savings and inv...
GSK plc Earnings Call Transcript: Q2 2026
Q2 saw 5% sales growth and strong cash generation, led by specialty medicines and vaccines. The Accelerate Growth program targets £1.9B in annual savings to fund R&D and protect margins through key LOE periods, while the Nuvalent acquisition expands the oncology pipeline.
GSK plc Quarterly report: Q2 2026
GSK plc has published its Q2 2026 quarterly earnings report on July 28, 2026.
GSK plc Slides: Q2 2026
GSK plc has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 28, 2026.
GSK Launches Cost-Saving Plan to Accelerate Drug Pipeline
The U.K. drugmaker is targeting annual savings of $2.52 billion by 2029, as Chief Executive Luke Miels outlined his roadmap to hit the company's 2031 sales target.
GSK sees 70p per share dividend for FY26
07:36 EDT GSK (GSK) sees 70p per share dividend for FY26
GSK initiates ‘Accelerate Growth’ program
The company said, “Following review, the company has identified asset accelerations – across 18 indications – for 7 late-stage products in Oncology, Respiratory, Hepatology and Vaccines. GSK (GSK) now...
GSK reports Q2 core EPS 50.5p, up 9% at CER
Reports Q2 revenue GBP 8.4B, +5% AER; +5% CER. “GSK (GSK) has delivered another quarter of strong core results performance, with our key growth drivers performing well.We remain focused on…
GSK beats second-quarter profit estimates, launches $2.52 billion cost savings drive
GSK on Tuesday beat second-quarter profit expectations and launched a £1.9 billion ($2.52 billion) cost savings drive as the British drugmaker seeks to ramp up its development pipeline to sup...
GSK to invest £400 million in Britain over 3 years as it ramps up R&D efforts
British drugmaker GSK said on Tuesday that it will invest £400 million ($531.12 million) over 3 years in the country, including a new R&D center in Cambridge as part of its plans to develop medicine...
GSK, Hansoh's cancer drug meets main goal of bone cancer trial
GSK on Tuesday said partner Hansoh Pharmaceutical's experimental drug Ris-Rez met its main goal of keeping an aggressive bone cancer from worsening in a late-stage trial, just weeks after ...